Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA ‘Brainstorms’ For Ways To Resume Pre-Pandemic Inspection Cadence

Executive Summary

The FDA's drug inspections director discusses trends and challenges in remarks at a Georgia GMP conference, while declining to share specific ideas generated in last week’s agency brainstorming session.

You may also be interested in...



US FDA Pharmaceutical Quality Operations Chief Outlines Paths To Quicker Inspections

As US pharmaceutical inspectorate advances toward pre-pandemic inspection cadence, there's new focus on accelerating site inspection process, as well as effort to improve retention with quicker, more targeted training. OPQO chief Alonza Cruse reviews key ideas at GMP conference.

US FDA's Cruse Outlines Paths To Quicker Inspections

As US pharmaceutical inspectorate advances toward its pre-pandemic inspection cadence, there is a new focus on accelerating the site inspection process, as well as an effort to improve retention with quicker, more targeted training. OPQO chief Alonza Cruse reviews key ideas at GMP conference.

Congress Explores Plans For Catching Up On US FDA Foreign Inspections

Absent agency said to have a plan to overcome vacancies and clear inspection backlog; subcommittee has other plans.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel